Cargando…
Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia
Although cure rates for pediatric acute lymphoblastic leukemia (ALL) have now risen to more than 90%, subsets of patients with high-risk features continue to experience high rates of treatment failure and relapse. Recent work in minimal residual disease stratification and leukemia genomics have incr...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268159/ https://www.ncbi.nlm.nih.gov/pubmed/32537116 http://dx.doi.org/10.1177/2040620720927575 |
_version_ | 1783541557243150336 |
---|---|
author | Karol, Seth E. Pui, Ching-Hon |
author_facet | Karol, Seth E. Pui, Ching-Hon |
author_sort | Karol, Seth E. |
collection | PubMed |
description | Although cure rates for pediatric acute lymphoblastic leukemia (ALL) have now risen to more than 90%, subsets of patients with high-risk features continue to experience high rates of treatment failure and relapse. Recent work in minimal residual disease stratification and leukemia genomics have increased the ability to identify and classify these high-risk patients. In this review, we discuss this work to identify and classify patients with high-risk ALL. Novel therapeutics, which may have the potential to improve outcomes for these patients, are also discussed. |
format | Online Article Text |
id | pubmed-7268159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72681592020-06-11 Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia Karol, Seth E. Pui, Ching-Hon Ther Adv Hematol Review Although cure rates for pediatric acute lymphoblastic leukemia (ALL) have now risen to more than 90%, subsets of patients with high-risk features continue to experience high rates of treatment failure and relapse. Recent work in minimal residual disease stratification and leukemia genomics have increased the ability to identify and classify these high-risk patients. In this review, we discuss this work to identify and classify patients with high-risk ALL. Novel therapeutics, which may have the potential to improve outcomes for these patients, are also discussed. SAGE Publications 2020-06-02 /pmc/articles/PMC7268159/ /pubmed/32537116 http://dx.doi.org/10.1177/2040620720927575 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Karol, Seth E. Pui, Ching-Hon Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia |
title | Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia |
title_full | Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia |
title_fullStr | Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia |
title_full_unstemmed | Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia |
title_short | Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia |
title_sort | personalized therapy in pediatric high-risk b-cell acute lymphoblastic leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268159/ https://www.ncbi.nlm.nih.gov/pubmed/32537116 http://dx.doi.org/10.1177/2040620720927575 |
work_keys_str_mv | AT karolsethe personalizedtherapyinpediatrichighriskbcellacutelymphoblasticleukemia AT puichinghon personalizedtherapyinpediatrichighriskbcellacutelymphoblasticleukemia |